Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sofiya Latifyan

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
EJNMMI Reports|August 3, 2025
Function of <sup>18</sup>F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)Clémence M C Huigen, Alexander Coukos, Sofiya Latifyan, et al.
Nature Communications|May 1, 2024
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinomaVictor Joo, Karim Abdelhamid, Alessandra Noto, et al.
Journal of Neurology|December 23, 2023
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case seriesAlex Vicino, Andreas F Hottinger, Sofiya Latifyan, et al.
Journal for Immunotherapy of Cancer|October 25, 2022
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse eventsAlexander Coukos, Julien Vionnet, Michel Obeid, et al.
Revue Medicale Suisse|January 11, 2019
[Oncology, what's new in 2018]Sofiya Latifyan, Artemisia Kakourou, Berna Ozdemir, et al.
Seminars in Oncology Nursing|May 24, 2025
Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors: Results from the IePRO Randomized Controlled TrialAndré Manuel da Silva Lopes, Stellio Giacomini, Ambily Ulahannan, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and GermanyJulia Maria Ressler, Matthias Karasek, Lukas Koch, et al.
Frontiers in Oncology|February 8, 2021
Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology TeamsDelphine Vuattoux, Sara Colomer-Lahiguera, Pierre-Alain Fernandez, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 22, 2023
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitorsAndré Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, et al.
JCO Clinical Cancer Informatics|May 5, 2023
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography ImagingDaniel Abler, Perrine Courlet, Matthieu Dietz, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
EJNMMI Reports|August 3, 2025
Function of <sup>18</sup>F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)Clémence M C Huigen, Alexander Coukos, Sofiya Latifyan, et al.
Nature Communications|May 1, 2024
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinomaVictor Joo, Karim Abdelhamid, Alessandra Noto, et al.
Journal of Neurology|December 23, 2023
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case seriesAlex Vicino, Andreas F Hottinger, Sofiya Latifyan, et al.
Journal for Immunotherapy of Cancer|October 25, 2022
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse eventsAlexander Coukos, Julien Vionnet, Michel Obeid, et al.
Revue Medicale Suisse|January 11, 2019
[Oncology, what's new in 2018]Sofiya Latifyan, Artemisia Kakourou, Berna Ozdemir, et al.
Seminars in Oncology Nursing|May 24, 2025
Acceptability of an Electronic Patient-Reported Outcomes-Based Model of Care to Monitor Symptoms Related to Cancer Treatment with Immune Checkpoint Inhibitors: Results from the IePRO Randomized Controlled TrialAndré Manuel da Silva Lopes, Stellio Giacomini, Ambily Ulahannan, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and GermanyJulia Maria Ressler, Matthias Karasek, Lukas Koch, et al.
Frontiers in Oncology|February 8, 2021
Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology TeamsDelphine Vuattoux, Sara Colomer-Lahiguera, Pierre-Alain Fernandez, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 22, 2023
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitorsAndré Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, et al.
JCO Clinical Cancer Informatics|May 5, 2023
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography ImagingDaniel Abler, Perrine Courlet, Matthieu Dietz, et al.
Pageof 3